help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hofbauer, L. C.
Right arrow Articles by Khosla, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hofbauer, L. C.
Right arrow Articles by Khosla, S.
Endocrinology Vol. 140, No. 10 4382-4389
Copyright © 1999 by The Endocrine Society

ARTICLES

Stimulation of Osteoprotegerin Ligand and Inhibition of Osteoprotegerin Production by Glucocorticoids in Human Osteoblastic Lineage Cells: Potential Paracrine Mechanisms of Glucocorticoid-Induced Osteoporosis1

Lorenz C. Hofbauer2, Francesca Gori, B. Lawrence Riggs, David L. Lacey, Colin R. Dunstan, Thomas C. Spelsberg and Sundeep Khosla

Endocrine Research Unit (L.C.H., F.G., B.L.R., S.K.) and Department of Biochemistry and Molecular Biology (T.C.S.), Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905; Amgen, Inc. (D.L.L., C.R.D.), Thousand Oaks, California 91320

Address all correspondence and requests for reprints to: Sundeep Khosla, M.D., Mayo Clinic and Mayo Foundation, Joseph 5–194, 200 First Street, S.W., Rochester, Minnesota 55905. E-mail: khosla{at}mayo.edu

Osteoporosis is a serious complication of systemic glucocorticoid use. However, while glucocorticoids increase bone resorption in vitro and in vivo, the mechanism(s) of this effect are at present unclear. Recent studies have identified the osteoprotegerin (OPG) ligand (OPG-L) as the final effector of osteoclastogenesis, an action that is opposed by the soluble neutralizing receptor, OPG. Thus, we assessed glucocorticoid regulation of OPG and OPG-L in various human osteoblastic lineage cells using Northern analysis, RT-PCR, and ELISA. Dexamethasone inhibited constitutive OPG messenger RNA (mRNA) steady-state levels by 70–90% in primary (MS) and immortalized stromal cells (hMS), primary trabecular osteoblasts (hOB), immortalized fetal osteoblasts (hFOB), and osteosarcoma cells (MG-63). In hFOB cells, dexamethasone inhibited constitutive OPG mRNA steady-state levels in a dose- and time-dependent fashion by 90%, and also suppressed cytokine-stimulated OPG mRNA steady-state levels. Dexamethasone-induced inhibition of OPG mRNA levels was not affected by the protein synthesis inhibitor, cycloheximide, and was shown to be due to inhibition of OPG gene transcription using a nuclear run-on assay. Moreover, dexamethasone also dose dependently (10-10 M–10-7 M) inhibited constitutive OPG protein concentrations in the conditioned medium of hFOB cells from 2.59 ± 0.02 ng/ml (control) to 0.30 ± 0.01 ng/ml (88% inhibition; P < 0.001 by ANOVA). Concurrently, dexamethasone stimulated OPG-L mRNA steady-state levels in MS and hFOB cells by 2- and 4-fold, respectively. Treatment of murine marrow cultures with conditioned medium harvested from dexamethasone-treated MG-63 cells increased tartrate-resistant acid phosphatase (TRAP) activity by 54% (P < 0.005) compared with medium harvested from control-treated cells (in the presence of OPG-L and macrophage colony-stimulating factor). Moreover, dexamethasone (10-8 M) promoted osteoclast formation in vitro, as assessed by a 2.5-fold increase of TRAP activity in cell lysates (P < 0.001) and the appearance of TRAP-positive multinucleated cells. Our data are thus consistent with the hypothesis that glucocorticoids promote osteoclastogenesis by inhibiting OPG and concurrently stimulating OPG-L production by osteoblastic lineage cells, thereby enhancing bone resorption.




This article has been cited by other articles:


Home page
 Mol. Endocrinol.Home page
R. D. Nerenz, M. L. Martowicz, and J. W. Pike
An Enhancer 20 Kilobases Upstream of the Human Receptor Activator of Nuclear Factor-{kappa}B Ligand Gene Mediates Dominant Activation by 1,25-Dihydroxyvitamin D3
Mol. Endocrinol., May 1, 2008; 22(5): 1044 - 1056.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
A. E. Kearns, S. Khosla, and P. J. Kostenuik
Receptor Activator of Nuclear Factor {kappa}B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease
Endocr. Rev., April 1, 2008; 29(2): 155 - 192.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
K. Horsch, H. de Wet, M. M. Schuurmans, F. Allie-Reid, A. C. B. Cato, J. Cunningham, J. M. Burrin, F. S. Hough, and P. A. Hulley
Mitogen-Activated Protein Kinase Phosphatase 1/Dual Specificity Phosphatase 1 Mediates Glucocorticoid Inhibition of Osteoblast Proliferation
Mol. Endocrinol., December 1, 2007; 21(12): 2929 - 2940.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. Vega, N. M. Maalouf, and K. Sakhaee
The Role of Receptor Activator of Nuclear Factor-{kappa}B (RANK)/RANK Ligand/Osteoprotegerin: Clinical Implications
J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4514 - 4521.
[Abstract] [Full Text] [PDF]

Home page
 J Am Acad Orthop SurgHome page
S. B. Goodman, W. Jiranek, E. Petrow, and A. W. Yasko
The Effects of Medications on Bone
J. Am. Acad. Ortho. Surg., August 1, 2007; 15(8): 450 - 460.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
P. Chavassieux, E. Seeman, and P. D. Delmas
Insights into Material and Structural Basis of Bone Fragility from Diseases Associated with Fractures: How Determinants of the Biomechanical Properties of Bone Are Compromised by Disease
Endocr. Rev., April 1, 2007; 28(2): 151 - 164.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
L. Mancini, M. J. Paul-Clark, G. Rosignoli, R. Hannon, J. E. Martin, I. Macintyre, and M. Perretti
Calcitonin and Prednisolone Display Antagonistic Actions on Bone and Have Synergistic Effects in Experimental Arthritis
Am. J. Pathol., March 1, 2007; 170(3): 1018 - 1027.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
M. B. Leonard
Glucocorticoid-Induced Osteoporosis in Children: Impact of the Underlying Disease
Pediatrics, March 1, 2007; 119(Supplement_2): S166 - S174.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
J. Cunningham
Pathogenesis and Prevention of Bone Loss in Patients Who Have Kidney Disease and Receive Long-Term Immunosuppression
J. Am. Soc. Nephrol., January 1, 2007; 18(1): 223 - 234.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
D. Jia, C. A. O'Brien, S. A. Stewart, S. C. Manolagas, and R. S. Weinstein
Glucocorticoids Act Directly on Osteoclasts to Increase Their Life Span and Reduce Bone Density
Endocrinology, December 1, 2006; 147(12): 5592 - 5599.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
S. Kim, M. Yamazaki, L. A. Zella, N. K. Shevde, and J. W. Pike
Activation of Receptor Activator of NF-{kappa}B Ligand Gene Expression by 1,25-Dihydroxyvitamin D3 Is Mediated through Multiple Long-Range Enhancers.
Mol. Cell. Biol., September 1, 2006; 26(17): 6469 - 6486.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
T. Kawai, T. Matsuyama, Y. Hosokawa, S. Makihira, M. Seki, N. Y. Karimbux, R. B. Goncalves, P. Valverde, S. Dibart, Y.-P. Li, et al.
B and T Lymphocytes Are the Primary Sources of RANKL in the Bone Resorptive Lesion of Periodontal Disease
Am. J. Pathol., September 1, 2006; 169(3): 987 - 998.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
C. Swanson, M. Lorentzon, H. H. Conaway, and U. H. Lerner
Glucocorticoid Regulation of Osteoclast Differentiation and Expression of Receptor Activator of Nuclear Factor-{kappa}B (NF-{kappa}B) Ligand, Osteoprotegerin, and Receptor Activator of NF-{kappa}B in Mouse Calvarial Bones
Endocrinology, July 1, 2006; 147(7): 3613 - 3622.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
J. Hjelmesaeth, T. Ueland, A. Flyvbjerg, J. Bollerslev, T. Leivestad, T. Jenssen, T. K. Hansen, S. Thiel, S. Sagedal, J. Roislien, et al.
Early Posttransplant Serum Osteoprotegerin Levels Predict Long-Term (8-Year) Patient Survival and Cardiovascular Death in Renal Transplant Patients
J. Am. Soc. Nephrol., June 1, 2006; 17(6): 1746 - 1754.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
B. P. Lukert
Glucocorticoid replacement--how much is enough?
J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 793 - 794.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Rogers and R. Eastell
Circulating Osteoprotegerin and Receptor Activator for Nuclear Factor {kappa}B Ligand: Clinical Utility in Metabolic Bone Disease Assessment
J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6323 - 6331.
[Abstract] [Full Text] [PDF]

Home page
 J. Dent. Res.Home page
S. Oka, Y. Kubota, T. Yamashiro, S. Ogata, T. Ninomiya, S. Ito, and K. Shirasuna
Effects of Positive Pressure in Odontogenic Keratocysts
J. Dent. Res., October 1, 2005; 84(10): 913 - 918.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
M. Freundlich, E. Alonzo, E. Bellorin-Font, and J. R. Weisinger
Increased Osteoblastic Activity and Expression of Receptor Activator of NF-{kappa}B Ligand in Nonuremic Nephrotic Syndrome
J. Am. Soc. Nephrol., July 1, 2005; 16(7): 2198 - 2204.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
S. Bonadonna, A. Burattin, M. Nuzzo, G. Bugari, E. A. Rosei, D. Valle, N. Iori, J. P Bilezikian, J. D Veldhuis, and A. Giustina
Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects
Eur. J. Endocrinol., February 1, 2005; 152(2): 199 - 205.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
O Di Munno, M Mazzantini, A D. Sedie, M Mosca, and S Bombardieri
Risk factors for osteoporosis in female patients with systemic lupus erythematosus
Lupus, September 1, 2004; 13(9): 724 - 730.
[Abstract] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Schoppet, N. Al-Fakhri, F. E. Franke, N. Katz, P. J. Barth, B. Maisch, K. T. Preissner, and L. C. Hofbauer
Localization of Osteoprotegerin, Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand, and Receptor Activator of Nuclear Factor-{kappa}B Ligand in Monckeberg's Sclerosis and Atherosclerosis
J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 4104 - 4112.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
L. C. Hofbauer and M. Schoppet
Clinical Implications of the Osteoprotegerin/RANKL/RANK System for Bone and Vascular Diseases
JAMA, July 28, 2004; 292(4): 490 - 495.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
O. Gluck and G. Colice
Recognizing and Treating Glucocorticoid-Induced Osteoporosis in Patients With Pulmonary Diseases
Chest, May 1, 2004; 125(5): 1859 - 1876.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. Hirotani, N. A. Tuohy, J.-T. Woo, P. H. Stern, and N. A. Clipstone
The Calcineurin/Nuclear Factor of Activated T Cells Signaling Pathway Regulates Osteoclastogenesis in RAW264.7 Cells
J. Biol. Chem., April 2, 2004; 279(14): 13984 - 13992.
[Abstract] [Full Text] [PDF]

Home page
 J. Dent. Res.Home page
J.Y.Y. Tay, B.H. Bay, J.F Yeo, M. Harris, S. Meghji, and S.T. Dheen
Identification of RANKL in Osteolytic Lesions of the Facial Skeleton
J. Dent. Res., April 1, 2004; 83(4): 349 - 353.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
C. A. O'Brien, D. Jia, L. I. Plotkin, T. Bellido, C. C. Powers, S. A. Stewart, S. C. Manolagas, and R. S. Weinstein
Glucocorticoids Act Directly on Osteoblasts and Osteocytes to Induce Their Apoptosis and Reduce Bone Formation and Strength
Endocrinology, April 1, 2004; 145(4): 1835 - 1841.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
J. Justesen, L. Mosekilde, M. Holmes, K. Stenderup, J. Gasser, J. J. Mullins, J. R. Seckl, and M. Kassem
Mice Deficient in 11{beta}-Hydroxysteroid Dehydrogenase Type 1 Lack Bone Marrow Adipocytes, but Maintain Normal Bone Formation
Endocrinology, April 1, 2004; 145(4): 1916 - 1925.
[Abstract] [Full Text] [PDF]

Home page
 Crit. Rev. Oral Biol. Med.Home page
U. H. Lerner
NEW MOLECULES IN THE TUMOR NECROSIS FACTOR LIGAND AND RECEPTOR SUPERFAMILIES WITH IMPORTANCE FOR PHYSIOLOGICAL AND PATHOLOGICAL BONE RESORPTION
Crit. Rev. Oral. Biol. Med., March 1, 2004; 15(2): 64 - 81.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
S. Rydziel, A. M. Delany, and E. Canalis
AU-Rich Elements in the Collagenase 3 mRNA Mediate Stabilization of the Transcript by Cortisol in Osteoblasts
J. Biol. Chem., February 13, 2004; 279(7): 5397 - 5404.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
L. B. Sher, H. W. Woitge, D. J. Adams, G. A. Gronowicz, Z. Krozowski, J. R. Harrison, and B. E. Kream
Transgenic Expression of 11{beta}-Hydroxysteroid Dehydrogenase Type 2 in Osteoblasts Reveals an Anabolic Role for Endogenous Glucocorticoids in Bone
Endocrinology, February 1, 2004; 145(2): 922 - 929.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Takuma, T. Kaneda, T. Sato, S. Ninomiya, M. Kumegawa, and Y. Hakeda
Dexamethasone Enhances Osteoclast Formation Synergistically with Transforming Growth Factor-{beta} by Stimulating the Priming of Osteoclast Progenitors for Differentiation into Osteoclasts
J. Biol. Chem., November 7, 2003; 278(45): 44667 - 44674.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
V. Viereck, C. Grundker, S. Blaschke, B. Niederkleine, H. Siggelkow, K.-H. Frosch, D. Raddatz, G. Emons, and L. C. Hofbauer
Raloxifene Concurrently Stimulates Osteoprotegerin and Inhibits Interleukin-6 Production by Human Trabecular Osteoblasts
J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4206 - 4213.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. S. Cooper, A. Blumsohn, P. E. Goddard, W. A. Bartlett, C. H. Shackleton, R. Eastell, M. Hewison, and P. M. Stewart
11{beta}-Hydroxysteroid Dehydrogenase Type 1 Activity Predicts the Effects of Glucocorticoids on Bone
J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3874 - 3877.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
K.-i. Hirose, H. Tomiyama, R. Okazaki, T. Arai, Y. Koji, G. Zaydun, S. Hori, and A. Yamashina
Increased Pulse Wave Velocity Associated with Reduced Calcaneal Quantitative Osteo-sono Index: Possible Relationship Between Atherosclerosis and Osteopenia
J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2573 - 2578.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
M. J. Coghlan, P. B. Jacobson, B. Lane, M. Nakane, C. W. Lin, S. W. Elmore, P. R. Kym, J. R. Luly, G. W. Carter, R. Turner, et al.
A Novel Antiinflammatory Maintains Glucocorticoid Efficacy with Reduced Side Effects
Mol. Endocrinol., May 1, 2003; 17(5): 860 - 869.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
O. Sezer, U. Heider, I. Zavrski, C. A. Kuhne, and L. C. Hofbauer
RANK ligand and osteoprotegerin in myeloma bone disease
Blood, March 15, 2003; 101(6): 2094 - 2098.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
B.-K. Choi, H. J. Lee, J. H. Kang, G. J. Jeong, C. K. Min, and Y.-J. Yoo
Induction of Osteoclastogenesis and Matrix Metalloproteinase Expression by the Lipooligosaccharide of Treponema denticola
Infect. Immun., January 1, 2003; 71(1): 226 - 233.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
N. S. Krieger, K. K. Frick, and D. A. Bushinsky
Cortisol Inhibits Acid-Induced Bone Resorption In Vitro
J. Am. Soc. Nephrol., October 1, 2002; 13(10): 2534 - 2539.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. R. Rubin and J. P. Bilezikian
The Role of Parathyroid Hormone in the Pathogenesis of Glucocorticoid-Induced Osteoporosis: A Re-Examination of the Evidence
J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4033 - 4041.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. Rubin, C. L. Ackert-Bicknell, L. Zhu, X. Fan, T. C. Murphy, M. S. Nanes, R. Marcus, L. Holloway, W. G. Beamer, and C. J. Rosen
IGF-I Regulates Osteoprotegerin (OPG) and Receptor Activator of Nuclear Factor-{kappa}B Ligand in Vitro and OPG in Vivo
J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4273 - 4279.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
T Mushtaq and S F Ahmed
The impact of corticosteroids on growth and bone health
Arch. Dis. Child., August 1, 2002; 87(2): 93 - 96.
[Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
M. Schoppet, K. T. Preissner, and L. C. Hofbauer
RANK Ligand and Osteoprotegerin: Paracrine Regulators of Bone Metabolism and Vascular Function
Arterioscler. Thromb. Vasc. Biol., April 1, 2002; 22(4): 549 - 553.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. M. Biskobing
COPD and Osteoporosis
Chest, February 1, 2002; 121(2): 609 - 620.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
E. Canalis and A. Giustina
Glucocorticoid-Induced Osteoporosis: Summary of a Workshop
J. Clin. Endocrinol. Metab., December 1, 2001; 86(12): 5681 - 5685.
[Full Text] [PDF]

Home page
 EndocrinologyHome page
S. Khosla
Minireview: The OPG/RANKL/RANK System
Endocrinology, December 1, 2001; 142(12): 5050 - 5055.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Coll. Nutr.Home page
B. A. Watkins, Y. Li, and M. F. Seifert
Nutraceutical Fatty Acids as Biochemical and Molecular Modulators of Skeletal Biology
J. Am. Coll. Nutr., October 1, 2001; 20(90005): 410S - 416.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
T. Yamagishi, E. Otsuka, and H. Hagiwara
Reciprocal Control of Expression of mRNAs for Osteoclast Differentiation Factor and OPG in Osteogenic Stromal Cells by Genistein: Evidence for the Involvement of Topoisomerase II in Osteoclastogenesis
Endocrinology, August 1, 2001; 142(8): 3632 - 3637.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
B. A. Watkins, Y. Li, H. E. Lippman, and M. F. Seifert
Omega-3 Polyunsaturated Fatty Acids and Skeletal Health
Experimental Biology and Medicine, June 1, 2001; 226(6): 485 - 497.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
N. Sasaki, E. Kusano, Y. Ando, K. Yano, E. Tsuda, and Y. Asano
Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis
Nephrol. Dial. Transplant., March 1, 2001; 16(3): 479 - 482.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
A. W. Eberhardt, A. Yeager-Jones, and H. C. Blair
Regional Trabecular Bone Matrix Degeneration and Osteocyte Death in Femora of Glucocorticoid- Treated Rabbits
Endocrinology, March 1, 2001; 142(3): 1333 - 1340.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
X. Fan, D. Fan, H. Gewant, C. L. Royce, M. S. Nanes, and J. Rubin
Increasing membrane-bound MCSF does not enhance OPGL-driven osteoclastogenesis from marrow cells
Am J Physiol Endocrinol Metab, January 1, 2001; 280(1): E103 - E111.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
F. Gori, L. C. Hofbauer, C. R. Dunstan, T. C. Spelsberg, S. Khosla, and B. L. Riggs
The Expression of Osteoprotegerin and RANK Ligand and the Support of Osteoclast Formation by Stromal-Osteoblast Lineage Cells Is Developmentally Regulated
Endocrinology, December 1, 2000; 141(12): 4768 - 4776.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
S. L. Teitelbaum
Bone Resorption by Osteoclasts
Science, September 1, 2000; 289(5484): 1504 - 1508.
[Abstract] [Full Text]

Home page
 Nephrol Dial TransplantHome page
E. A. Gonzalez
The role of cytokines in skeletal remodelling: possible consequences for renal osteodystrophy
Nephrol. Dial. Transplant., July 1, 2000; 15(7): 945 - 950.
[Full Text] [PDF]

Home page
 Endocr. Rev.Home page
S. C. Manolagas
Birth and Death of Bone Cells: Basic Regulatory Mechanisms and Implications for the Pathogenesis and Treatment of Osteoporosis
Endocr. Rev., April 1, 2000; 21(2): 115 - 137.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
S. C. Manolagas
Editorial: Cell Number Versus Cell Vigor--What Really Matters to a Regenerating Skeleton?
Endocrinology, October 1, 1999; 140(10): 4377 - 4381.
[Full Text]

Home page
 J. Biol. Chem.Home page
H. Zhou, V. Kartsogiannis, Y. S. Hu, J. Elliott, J. M. W. Quinn, W. J. McKinstry, M. T. Gillespie, and K. W. Ng
A Novel Osteoblast-derived C-type Lectin That Inhibits Osteoclast Formation
J. Biol. Chem., April 27, 2001; 276(18): 14916 - 14923.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
M. Schoppet, K. T. Preissner, and L. C. Hofbauer
RANK Ligand and Osteoprotegerin: Paracrine Regulators of Bone Metabolism and Vascular Function
Arterioscler. Thromb. Vasc. Biol., April 1, 2002; 22(4): 549 - 553.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1999 by The Endocrine Society